Bial-portela Ca & S.a.

Bial-portela & Cª, S.a.

Other

Portela, C.a., S.a.

Laszlo Erno Kiss

Pedro Nuno Leal Palma

David Alexander Learmonth

Humberto Dos Santos Ferreira

Patricio Manuel Vieira Araujo Soares Da Silva

Jorge Bruno Reis Wahnon

Domenico Russo

Alexander Beliaev

William Maton

Carla Patricia Da Costa Pereira Rosa

Rita Gusmao De Noronha

Tino Rossi

Patricio Manuel V A Soares Da Silva

Michael Kreis

Klaus Reiter

Tibor Eszenyi

Bjoern Schlummer

Axel Zimmermann

Patrício Soares Da Silva

Carla Patricia Rosa

Patricio Manuel Araujo Soares Da Silva

Patrício Manuel Vieira Araújo Soares Da Silva

Patricio Manuel Vieira Araújo Soares Da Silva

Carla Patrícia Da Costa Pereira Rosa

Rita Gusmãmo De Noronha

Patrício Manuel Vieira Araujo Soares Da Silva

Rui Pinto

Francisco Cardona

Rita Gusmão De Noronha

Patrício Manuel Vieira ARAÚJO Soares Da Silva

Rita GUSMÃO De Noronha

Klaus Rieter

Pedro Nuno Palma

Axel Zimmerman

Patricio Manuel Soares Da Silva

This invention relates to: (a) compounds of formula Ia (with R1, R4 to R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-&#x3b2;-hydroxylase inhibitors; (b) pharmaceutical compositions (comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds. 

Dopamine-b-hydroxylase inhibitors

A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

Urea compounds and their use as enzyme inhibitors

This invention relates to: (a) compounds of Formula Ia (with R1, R4, R5, R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-&#x3b2;-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds. 

Dopamine-&#x3b2;-hydroxylase inhibitors

This invention relates to: (a) compounds of formula (I) (with Rto R, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-&#x3b2;-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds. 

Blood-brain barrier-penetrant dopamine-&#x3b2;-hydroxylase inhibitors

A compound having a structure selected from the following: or a pharmaceutically acceptable salt thereof. The compound may be used as an inhibitor of fatty acid amide hydrolase.

Imidazolecarboxamides  and their use as FAAH inhibitors

New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

Nitrocatechol derivatives as COMT inhibitors

The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day.

Dosage regimen for COMT inhibitors

There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.

Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor

This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.

Pharmaceutical compounds

The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to substrates of the FAAH enzyme, and methods of treatment or prevention using the compounds and compositions.

Intermediate for preparing a catechol-O-methyltransferase inhibitor

Growing community of inventors

S. Mamede do Coronado, Portugal

Laszlo Erno Kiss